ArticleEMBO molecular medicine2017
A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms.
Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Lcn2 deficiency leads to long-lasting social impairments independent of maternal immune activation.Journal of neuroinflammation · 2026Article
- MMP9 Genetic Variants in Schizophrenia Spectrum Disorders and Its Relation with Cognitive Dysfunction and Suicide Attempt.Indian journal of psychological medicine · 2026Article
- ALife science alliance · 2025Article
- Alterations in the plasma concentrations of BDNF, proBDNF, and MMP-9 in patients with schizophrenia.European journal of medical research · 2025Article
- BDNF-driven synaptic plasticity requires autocrine matrix metalloproteinase-9 activity.Science advances · 2025Article
- Elevated plasma matrix metalloproteinase 9 in schizophrenia patients associated with poor antipsychotic treatment response and white matter density deficits.Schizophrenia (Heidelberg, Germany) · 2024Article
- Synaptic cell adhesion molecules contribute to the pathogenesis and progression of fragile X syndrome.Frontiers in cellular neuroscience · 2024Review
- Dysregulation of Synaptic Plasticity Markers in Schizophrenia.Indian journal of clinical biochemistry : IJCB · 2023Review
- The emerging role of furin in neurodegenerative and neuropsychiatric diseases.Translational neurodegeneration · 2022Review
- Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment.Molecular neurobiology · 2022Article
- Quantification of Dendritic Spines Remodeling under Physiological Stimuli and in Pathological Conditions.International journal of molecular sciences · 2021Review
- Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia.Neuropsychopharmacology reports · 2020Article
- Protein Translation and Psychiatric Disorders.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2020Review
- Variants inAnimals : an open access journal from MDPI · 2019Article
- MMPs in learning and memory and neuropsychiatric disorders.Cellular and molecular life sciences : CMLS · 2019Review
- Psychosocial Stress Induces Schizophrenia-Like Behavior in Mice With Reduced MMP-9 Activity.Frontiers in behavioral neuroscience · 2019Article
- DNA Methylation and Gene Expression of Matrix Metalloproteinase 9 Gene in Deficit and Non-deficit Schizophrenia.Frontiers in genetics · 2018Article
- The Perineuronal 'Safety' Net? Perineuronal Net Abnormalities in Neurological Disorders.Frontiers in molecular neuroscience · 2018Review
- Shaping Synapses by the Neural Extracellular Matrix.Frontiers in neuroanatomy · 2018Review
- Haloperidol Abrogates Matrix Metalloproteinase-9 Expression by Inhibition of NF-Mediators of inflammation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinase 9 (MMP-9) has recently emerged as a molecule that contributes to pathological synaptic plasticity in schizophrenia, but explanation of the underlying mechanisms has been missing. In the present study, we performed a phenotype-based genetic association study (PGAS) in > 1,000 schizophrenia patients from the Göttingen Research Association for Schizophrenia (GRAS) data collection and found an association between the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.